Skip to main content

Celgene Value Stock - Dividend - Research Selection


ISIN: US1510201049, WKN: 881244

Market price date: 30.11.-0001
Market price: 0,00 USD

Celgene Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2019
Cash flow
Net operating cash flow
Capital Expenditures -330.000.000
Free cash flow 4.840.999.936
Balance sheet
Total Equity
Liabilities & Shareholders equity 35.480.000.000
Income statement
Net income
Eps (diluted) 5,510
Diluted shares outstanding 733.800.000
Net sales/revenue

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization79.426.510.848,00 USD
Raw Data Source
Stock Split

Description of the company

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Pfizer's bowel disease drug succeeds in second late-stage study

Pfizer Inc said on Tuesday its experimental treatment for an inflammatory bowel disease, acquired last year as part of its $6.7 billion Arena Pharmaceuticals deal, succeeded in a second late-stage study.